APELLIS PHARMACEUTICALS INC (APLS)       54.77  -1.96 (-3.45%)

Noteworthy Friday Option Activity: AMD, APLS, UPS

Notable Thursday Option Activity: APLS, HUM, MMM

Noteworthy Thursday Option Activity: BTU, APLS, COF

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

Apellis appoints Baumal as Chief Medical Officer (NASDAQ:APLS)

Apellis Pharmaceuticals (APLS) notifies that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

APLS stock, ARVN stock downgraded at Wells Fargo (NASDAQ:APLS)

Apellis Pharmaceuticals (APLS) and Arvinas (ARVN) slipped on Tuesday after Wells Fargo downgraded the biotechs to Equal Weight from Overweight. Read the full story here.

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

Apellis Pharmaceuticals Moves Up In Market Cap Rank, Passing Alaska Air Group

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment

The delay is at Apellis' behest. The company wanted to include updated data in its request.

Apellis stock rises 17% as FDA accepts to review new data for eye drug

Apellis Pharmaceuticals (APLS) said the U.S. Food and Drug Administration (FDA) accepted the company's additional data filed for an application seeking approval...

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Notable Monday Option Activity: APLS, AZO, RILY

APLS stock ISEE stock cut to Hold at Jefferies on overestimated GA market (NASDAQ:APLS)

Jefferies downgraded Apellis Pharmaceuticals (APLS) and IVERIC bio (ISEE) on Thursday from Buy to Hold, arguing that investors appear to have over-modeled the market prospects of each...